Showing results (1-10 of 46) with videos related to
Sort By:
Pageof 5
International Journal of Radiation Oncology, Biology, Physics|December 3, 2002
The development of combretastatin A4 phosphate as a vascular targeting agentDavid J Chaplin, Sally A HillExpert Opinion on Drug Discovery|March 15, 2013
An update on the clinical development of drugs to disable tumor vasculatureDietmar W Siemann, David J ChaplinExpert Opinion on Investigational Drugs|August 28, 2004
Combretastatin A4 phosphate: background and current clinical statusScott L Young, David J ChaplinAnticancer Research|May 17, 2002
Influence of hypoxia and tumour-conditioned medium on endothelial cell adhesion molecule expression in vitroMargaret E Watts, Charles S Parkins, David J ChaplinCancer Research|March 5, 2003
The first international conference on vascular targeting: meeting overviewPhilip E Thorpe, David J Chaplin, David C BlakeyExpert Opinion on Investigational Drugs|February 25, 2009
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)Dietmar W Siemann, David J Chaplin, Patricia A WalickeGynecologic Oncology|February 28, 2017
The development and use of vascular targeted therapy in ovarian cancerDana M Chase, David J Chaplin, Bradley J MonkCancer|June 16, 2004
Vascular-targeting therapies for treatment of malignant diseaseDietmar W Siemann, David J Chaplin, Michael R HorsmanCurrent Opinion in Investigational Drugs (London, England : 2000)|June 21, 2006
Current development status of small-molecule vascular disrupting agentsDavid J Chaplin, Michael R Horsman, Dietmar W SiemannInternational Journal of Cancer|September 28, 2002
Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour modelsSally A Hill, David J Chaplin, Gemma Lewis, et al.Pageof 5